These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9071897

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T, Shousha S.
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [Abstract] [Full Text] [Related]

  • 3. Is there a low-grade precursor pathway in breast cancer?
    King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [Abstract] [Full Text] [Related]

  • 4. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
    Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Baldetorp B, Linden T, Hansen B, Andersen J.
    Breast Cancer Res Treat; 2000 Apr; 60(3):219-26. PubMed ID: 10930109
    [Abstract] [Full Text] [Related]

  • 5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003 Apr; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I.
    Cancer Detect Prev; 1998 Apr; 22(4):313-8. PubMed ID: 9674874
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L, Kerkvliet N, Doig G, O'Malley FP.
    Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
    [Abstract] [Full Text] [Related]

  • 17. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F, Rose IM, Masir N.
    Asian Pac J Cancer Prev; 2015 Aug; 16(6):2385-90. PubMed ID: 25824769
    [Abstract] [Full Text] [Related]

  • 18. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma.
    Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, Soini Y.
    APMIS; 2004 Feb; 112(2):123-32. PubMed ID: 15056229
    [Abstract] [Full Text] [Related]

  • 19. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P.
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.